Background: Patients with CKD ha ve impaired immunity, increased risk of infection-related mortality, and worsened COVID-19 outcomes. However, data comparing nondialysis CKD and ESKD are sparse. Methods: Patients with COVID-19 admitted to three hospitals in the New York area, between March 2 and August 27, 2020, were retrospectively studied using electronic health records. Patients were classified as those without CKD, those with nondialysis CKD, and those with ESKD, with outcomes including hospital mortality, ICU admission, and mortality rates. Results: Of 3905 patients, 588 (15%) had nondialysis CKD and 128 (3%) had ESKD. The nondialysis CKD and ESKD groups had a greater prevalence of comorbidities and higher admission D-dimer levels, whereas patients with ESKD had lower C-reactive protein levels at admission. ICU admission rates were similar across all three groups (23%-25%). The overall, unadjusted hospital mortality was 25%, and the mortality was 24% for those without CKD, 34% for those with nondialysis CKD, and 27% for those with ESKD. Among patients in the ICU, mortality was 56%, 64%, and 56%, respectively. Although patients with nondialysis CKD had higher odds of overall mortality versus those without CKD in univariate analysis (OR, 1.58; 95% CI, 1.31 to 1.91), this was no longer significant in fully adjusted models (OR, 1.11; 95% CI, 0.88 to 1.40). Also, ESKD status did not associate with a higher risk of mortality compared with non-CKD in adjusted analyses, but did have reduced mortality when compared with nondialysis CKD (OR, 0.57; 95% CI, 0.33 to 0.95). Mortality rates declined precipitously after the first 2 months of the pandemic, from 26% to 14%, which was reflected in all three subgroups. Conclusions: In a diverse cohort of patients with COVID-19, we observed higher crude mortality rates for patients with nondialysis CKD and, to a lesser extent, ESKD, which were not significant after risk adjustment. Moreover, patients with ESKD appear to have better outcom es than those with nondialysis CKD.
Background: Patients with CKD ha ve impaired immunity, increased risk of infection-related mortality, and worsened COVID-19 outcomes. However, data comparing nondialysis CKD and ESKD are sparse. Methods: Patients with COVID-19 admitted to three hospitals in the New York area, between March 2 and August 27, 2020, were retrospectively studied using electronic health records. Patients were classified as those without CKD, those with nondialysis CKD, and those with ESKD, with outcomes including hospital mortality, ICU admission, and mortality rates. Results: Of 3905 patients, 588 (15%) had nondialysis CKD and 128 (3%) had ESKD. The nondialysis CKD and ESKD groups had a greater prevalence of comorbidities and higher admission D-dimer levels, whereas patients with ESKD had lower C-reactive protein levels at admission. ICU admission rates were similar across all three groups (23%-25%). The overall, unadjusted hospital mortality was 25%, and the mortality was 24% for those without CKD, 34% for those with nondialysis CKD, and 27% for those with ESKD. Among patients in the ICU, mortality was 56%, 64%, and 56%, respectively. Although patients with nondialysis CKD had higher odds of overall mortality versus those without CKD in univariate analysis (OR, 1.58; 95% CI, 1.31 to 1.91), this was no longer significant in fully adjusted models (OR, 1.11; 95% CI, 0.88 to 1.40). Also, ESKD status did not associate with a higher risk of mortality compared with non-CKD in adjusted analyses, but did have reduced mortality when compared with nondialysis CKD (OR, 0.57; 95% CI, 0.33 to 0.95). Mortality rates declined precipitously after the first 2 months of the pandemic, from 26% to 14%, which was reflected in all three subgroups. Conclusions: In a diverse cohort of patients with COVID-19, we observed higher crude mortality rates for patients with nondialysis CKD and, to a lesser extent, ESKD, which were not significant after risk adjustment. Moreover, patients with ESKD appear to have better outcom es than those with nondialysis CKD.
Authors: Marcello Tonelli; Natasha Wiebe; Bruce Culleton; Andrew House; Chris Rabbat; Mei Fok; Finlay McAlister; Amit X Garg Journal: J Am Soc Nephrol Date: 2006-05-31 Impact factor: 10.121
Authors: Richard W Corbett; Sarah Blakey; Dorothea Nitsch; Marina Loucaidou; Adam McLean; Neill Duncan; Damien R Ashby Journal: J Am Soc Nephrol Date: 2020-06-19 Impact factor: 10.121
Authors: Marian Goicoechea; Luis Alberto Sánchez Cámara; Nicolás Macías; Alejandra Muñoz de Morales; Ángela González Rojas; Arturo Bascuñana; David Arroyo; Almudena Vega; Soraya Abad; Eduardo Verde; Ana María García Prieto; Úrsula Verdalles; Diego Barbieri; Andrés Felipe Delgado; Javier Carbayo; Antonia Mijaylova; Adriana Acosta; Rosa Melero; Alberto Tejedor; Patrocinio Rodriguez Benitez; Ana Pérez de José; María Luisa Rodriguez Ferrero; Fernando Anaya; Manuel Rengel; Daniel Barraca; José Luño; Inés Aragoncillo Journal: Kidney Int Date: 2020-05-11 Impact factor: 10.612
Authors: Matthew J Cummings; Matthew R Baldwin; Darryl Abrams; Samuel D Jacobson; Benjamin J Meyer; Elizabeth M Balough; Justin G Aaron; Jan Claassen; LeRoy E Rabbani; Jonathan Hastie; Beth R Hochman; John Salazar-Schicchi; Natalie H Yip; Daniel Brodie; Max R O'Donnell Journal: Lancet Date: 2020-05-19 Impact factor: 79.321
Authors: Michael G Argenziano; Samuel L Bruce; Cody L Slater; Jonathan R Tiao; Matthew R Baldwin; R Graham Barr; Bernard P Chang; Katherine H Chau; Justin J Choi; Nicholas Gavin; Parag Goyal; Angela M Mills; Ashmi A Patel; Marie-Laure S Romney; Monika M Safford; Neil W Schluger; Soumitra Sengupta; Magdalena E Sobieszczyk; Jason E Zucker; Paul A Asadourian; Fletcher M Bell; Rebekah Boyd; Matthew F Cohen; MacAlistair I Colquhoun; Lucy A Colville; Joseph H de Jonge; Lyle B Dershowitz; Shirin A Dey; Katherine A Eiseman; Zachary P Girvin; Daniella T Goni; Amro A Harb; Nicholas Herzik; Sarah Householder; Lara E Karaaslan; Heather Lee; Evan Lieberman; Andrew Ling; Ree Lu; Arthur Y Shou; Alexander C Sisti; Zachary E Snow; Colin P Sperring; Yuqing Xiong; Henry W Zhou; Karthik Natarajan; George Hripcsak; Ruijun Chen Journal: BMJ Date: 2020-05-29
Authors: Geehan Suleyman; Raef A Fadel; Kelly M Malette; Charles Hammond; Hafsa Abdulla; Abigail Entz; Zachary Demertzis; Zachary Hanna; Andrew Failla; Carina Dagher; Zohra Chaudhry; Amit Vahia; Odaliz Abreu Lanfranco; Mayur Ramesh; Marcus J Zervos; George Alangaden; Joseph Miller; Indira Brar Journal: JAMA Netw Open Date: 2020-06-01
Authors: Chiara Cantarelli; Andrea Angeletti; Laura Perin; Luis Sanchez Russo; Gianmarco Sabiu; Manuel Alfredo Podestà; Paolo Cravedi Journal: Clin Kidney J Date: 2022-07-27